Anesthetic management of glucose 6-phosphate dehydrogenase deficiency

S Gómez Gómez1, M Ruano Santiago1, A Rodríguez Morillo1

  • 1Servicio de Anestesiología, Reanimación y Terapéutica del dolor, Hospital Universitario de Valme, Sevilla, Spain.

Insights

Glucose 6-phosphate dehydrogenase deficiency affects 400 million worldwide, primarily men. Anesthetic management is crucial for safe surgical interventions in these patients.

Area of Science:

  • Biochemistry
  • Hematology
  • Genetics

Background:

  • Glucose 6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme disorder, affecting red blood cells.
  • Inherited on the X chromosome, it predominantly impacts males globally, with approximately 400 million individuals affected.
  • G6PD is vital for the pentose-phosphate pathway, maintaining cellular metabolism and antioxidant production.

Observation:

  • G6PD deficiency impairs red blood cells' defense against oxidative stress from drugs, infections, or metabolic issues.
  • Patients with G6PD deficiency require specific anesthetic considerations for medical-surgical procedures.
  • This article details a case of a 45-year-old male with G6PD deficiency undergoing combined general anesthesia for rectal surgery.

Findings:

  • The study highlights the necessity of tailored anesthetic protocols for patients with G6PD deficiency.
  • Effective management can mitigate risks associated with oxidative stress during surgery.
  • Successful combined general anesthesia was administered for a low anterior resection in a G6PD-deficient patient.

Implications:

  • Understanding G6PD's role in oxidative stress is key for managing affected individuals.
  • Anesthesiologists must be aware of potential complications and adjust techniques accordingly.
  • This case underscores the importance of pre-operative evaluation and individualized anesthetic planning for G6PD deficiency.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
308
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
359
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
177
General Anesthesia: Overview01:24

General Anesthesia: Overview

Anesthesia is a medical procedure that uses drugs for CNS suppression to enable painless surgeries and procedures. The selection of anesthetics is influenced by their pharmacokinetic properties, side effects, and patient characteristics. Various types of anesthesia include general, local, regional, spinal, and inhalational.
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
261
Glycolysis: Preparatory Phase01:21

Glycolysis: Preparatory Phase

In cellular metabolism (the complete breakdown of glucose to extract energy),  glycolysis is the first step. Glycolysis takes place in the cytoplasm of both prokaryotic and eukaryotic cells. Glucose enters heterotrophic cells in two ways. One method is through secondary active transport, where the transport takes place against the glucose concentration gradient. The other mechanism uses a group of integral proteins called GLUT proteins, also known as glucose transporter proteins. These...
13.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
228